Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:33:34.461Z.
Calculation as of: 2026-10-06T16:33:34.461Z.
Quote observation: 2026-10-06T16:30:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1ca0602d484fef860d1886a06048f849113dfee726f77a026e2ec96edb2346c6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$82.82M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.85M
EBITDA Yield
N/A
TTM Avg
8.07%
3Y Avg
4.72%
5Y Avg
4.72%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MediciNova, Inc. (MNOV) | $82.45M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.72M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.82M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $82.05M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.62M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.18M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $83.85M | N/A | 8.07% | 4.72% | 4.72% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.57M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $79.82M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
